Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective–a Commentary

Clark, IA; Vissel, B

Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective–a Commentary

Clark, IA Vissel, B

Permalink

Publication Type:: Journal Article
Citation:: Expert Review of Neurotherapeutics, 2019, 19 (6), pp. 535 - 543
Issue Date:: 2019-06-03

Closed Access

	Filename	Description	Size
	Neurodegenerative disease treatments by direct TNF reduction SB623 cells maraviroc and irisin and MCC950 from an inflammatory perspective a Commentary.pdf	Published Version	1.09 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Clark, IA	en_US
dc.contributor.author	Vissel, B https://orcid.org/0000-0001-8860-8050	en_US
dc.date.issued	2019-06-03	en_US
dc.identifier.citation	Expert Review of Neurotherapeutics, 2019, 19 (6), pp. 535 - 543	en_US
dc.identifier.issn	1473-7175	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136154
dc.description.abstract	© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Introduction: The importance of excessive cerebral tumor necrosis factor (TNF) concentrations as one of the central tenets of the pathogenesis of the neurodegenerative diseases is now widely known, but variably accepted. Areas covered: Here we update the field by including material that is freely available on the large databases, particularly PubMed. We include the therapeutic outcomes with etanercept (a widely used specific anti-TNF biological), XPro1595 (a new double negative TNF inhibitor), 3,61-dithiothalidomide, implanted SB623 stem cells, maraviroc (a CCR5 inhibitor used to treat AIDS), MCC950 (an NLRP3 inhibitor), and changes in the hormone irisin. Expert opinion: Remarkably, considering the ample literature that links SB623 cells, maraviroc, MCC950 and irisin to TNF, these publications do not mention this cytokine, and therefore not their implicit involvement with controlling its cerebral levels. With regard to developments demonstrated by MCC950, we note that DAMPs and PAMPs recognize and activate both TLRs and inflammasomes in these disease states. Here, as in other illnesses, data suggests that preventing a pathogenic interaction could be achieved through shutting down either of these arms of innate immunity.	en_US
dc.relation.ispartof	Expert Review of Neurotherapeutics	en_US
dc.relation.isbasedon	10.1080/14737175.2019.1618710	en_US
dc.subject.classification	Neurology & Neurosurgery	en_US
dc.title	Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective–a Commentary	en_US
dc.type	Journal Article
utslib.citation.volume	6	en_US
utslib.citation.volume	19	en_US
utslib.for	1109 Neurosciences	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access
pubs.issue	6	en_US
pubs.publication-status	Published	en_US
pubs.volume	19	en_US

Abstract:

© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Introduction: The importance of excessive cerebral tumor necrosis factor (TNF) concentrations as one of the central tenets of the pathogenesis of the neurodegenerative diseases is now widely known, but variably accepted. Areas covered: Here we update the field by including material that is freely available on the large databases, particularly PubMed. We include the therapeutic outcomes with etanercept (a widely used specific anti-TNF biological), XPro1595 (a new double negative TNF inhibitor), 3,61-dithiothalidomide, implanted SB623 stem cells, maraviroc (a CCR5 inhibitor used to treat AIDS), MCC950 (an NLRP3 inhibitor), and changes in the hormone irisin. Expert opinion: Remarkably, considering the ample literature that links SB623 cells, maraviroc, MCC950 and irisin to TNF, these publications do not mention this cytokine, and therefore not their implicit involvement with controlling its cerebral levels. With regard to developments demonstrated by MCC950, we note that DAMPs and PAMPs recognize and activate both TLRs and inflammasomes in these disease states. Here, as in other illnesses, data suggests that preventing a pathogenic interaction could be achieved through shutting down either of these arms of innate immunity.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136154